UBS Group’s BridgeBio Pharma BBIO Stock Holding History

UBS Group’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$287M	Hold	3,863,500	–	–	0.04%	448
2025 Q4	$296M	Hold	3,863,500	–	–	0.05%	390
2025 Q3	$201M	Hold	3,863,500	–	–	0.03%	581
2025 Q2	$167M	Sell	3,863,500 -22,700	-0.6%	-$826K	0.03%	624
2025 Q1	$134M	Sell	3,886,200 -115,600	-3%	-$3.9M	0.02%	729
2024 Q4	$110M	Sell	4,001,800 -107,500	-3%	-$2.78M	0.02%	863
2024 Q3	$105M	Buy	4,109,300 +245,800	+6%	+$6.45M	0.02%	697
2024 Q2	$97.9M	Hold	3,863,500	–	–	0.02%	664
2024 Q1	$119M	Buy	+3,863,500	New	+$131M	0.03%	568
2023 Q3	–	Sell	-12,100	Closed	-$208K	–	9451
2023 Q2	$208K	Buy	+12,100	New	+$182K	﹤0.01%	5450
2022 Q1	–	Sell	-4,900	Closed	-$82K	–	10243
2021 Q4	$82K	Buy	+4,900	New	+$207K	﹤0.01%	6481

Other funds holding BBIO

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

KKRC

Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

DAM

Diamant Asset Management Ridgefield, Connecticut $137B AUM 18.02% 1-Year Est. Return

ACM

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

UBS Group's BBIO Position: Q1 2026 in Review

UBS Group increased its BridgeBio Pharma (BBIO) stake by 8.1% in Q1 2026, buying an estimated $11M and bringing the position to 2,026,821 shares worth $151M. The position accounts for 0.02% of the portfolio, ranked #769.

UBS Group first reported a position in BBIO in Q2 2019 and has held it in 28 quarters since. 457 funds tracked by Wall St. Rank hold BBIO as of Q1 2026.

UBS Group held 2,026,821 shares of BridgeBio Pharma worth $151M as of Q1 2026.
UBS Group bought 151,156 BridgeBio Pharma shares in Q1 2026, an estimated $11M.
BridgeBio Pharma made up 0.02% of UBS Group's portfolio in Q1 2026, its #769 holding.
UBS Group first reported a position in BridgeBio Pharma in Q2 2019 and has held it in 28 quarters since.
457 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.